Pharmacogenomics: Precision Pharmacy in 503A Compounding
Author(s): Drummond Joseph, Bennet Daron, Allen Loyd V Jr
Issue: Mar/Apr 2018 - Volume 22, Number 2
View All Articles in Issue
Page(s): 95-107
Download in electronic PDF format for $75
Abstract: The first recorded mention of a pharmacogenomic response may be that of Pythagoras in 510 BC, when he noted that hemolytic anemia developed in some but not all people who ingested fava beans. The application of such accounts to pharmacotherapy was inevitable, and customized medications have been compounded since antiquity to treat the needs of individual patients. Today, advances in pharmacogenomic testing yield results that enable more effective targeted therapies sooner in the course of treatment, prevent drug-related adverse effects, save cost, and ensure a better therapeutic outcome. The value of such testing is now more widely accepted, even in the public domain. It is our opinion that third-party payors will realize, to an increasing degree, that this new technology will save them money and will pay for it. Because independent compounding pharmacists have trusted relationships with patients and are convenient to visit, they are well placed to offer certain types of pharmacogenomic tests to patients and prescribers. In this article, topics that we address include the difference between pharmacogenomics and pharmacogenetics; the use of pharmacogenomic testing in 503A compounding; the benefits of such tests for patients, prescribers, and compounders; and suggestions for marketing pharmacogenomics testing. Information about a course that introduces pharmacogenomic science to compounders is provided, and suggestions for additional reading and other resources about pharmacogenomic testing are included for easy reference.
Related Keywords:
precision medicine, customized medications, personalized medicine, pharmacogenomic testing, pharmacogenetics, continuing education, drug-gene interactions, drug-drug interactions, drug-lifestyle interactions, drug safety, adverse effects, side effects
Related Categories:
BUSINESS, MARKETING, TECHNOLOGY, PATIENT ASSESSMENT, PROFESSIONAL ISSUES, INFORMATION RESOURCES
Printer-Friendly Version
Related Articles from IJPC |
Title/Author
(Click for Abstract / Details / Purchase) |
Issue/Page
View/Buy |
Pharmacogenomics: Precision Pharmacy in 503A Compounding
Drummond Joseph, Bennet Daron, Allen Loyd V Jr
|
Mar/Apr 2018
Pg. 95-107
|
Personalized Medicine and Customized Drug Delivery Systems: The New Trend of Drug Delivery and Disease Management
Soni Abhishek, Gowthamarajan Kuppusamy, Radhakrishnan Arun
|
Mar/Apr 2018
Pg. 108-121
|
Veterinary Transdermal Medications: A to Z
Davidson Gigi S
|
Mar/Apr 2003
Pg. 106-113
|
PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs
Allen Loyd V Jr
|
Sep/Oct 2017
Pg. 356
|
Final Guidance for Pharmacy Compounding of Human Drug Products Under Section 503A
Blankenship Cynthia E
|
Sep/Oct 2014
Pg. 379-380
|
Pharmacogenomics as a Competitive Strategy for Compounding Pharmacies
Maham Nicole Y
|
Nov/Dec 2022
Pg. 474-479
|
Biotechnology, Nanotechnology, and Pharmacogenomics and Pharmaceutical Compounding, Part 2
Allen Loyd V
|
Jul/Aug 2015
Pg. 280-287
|
Quality Control: Personal Protective Equipment for Use When Handling Hazardous Drugs
Dillon L R
|
Jan/Feb 2020
Pg. 30-36
|
Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines
Allen Loyd V Jr
|
Jul/Aug 2016
Pg. 351
View Sample |
U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies
Yoch Doug
|
Mar/Apr 2017
Pg. 95-102
|
Does Your Drug Expertise Include Clinical Pharmaceutics?
Newton David W
|
May/Jun 2016
Pg. 202-206
|
PostScription: Drug Disposal: Compounding Pharmacists' Involvement in the Prevention of Prescription Drug Misuse and Abuse
Williams LaVonn A
|
Nov/Dec 2011
Pg. 526-527
|
U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs
Allen Loyd V Jr
|
Nov/Dec 2015
Pg. 487-488
|
Determining Whether a Substance is Legal to Compound with Under Section 503A of the FDCA
Cabaleiro Joe
|
Sep/Oct 2021
Pg. 358-362
|
Drug Shortage Compounding: The Only Safe Medication Source in a Time of Crisis
Lyon Joanna
|
Nov/Dec 2012
Pg. 456-460
|
Allowing Compounding Pharmacies to Address Drug Shortages
Broughel James
|
Mar/Apr 2022
Pg. 100-109
|
The Role of Compounding Pharmacists During Drug Shortages
Ofei Kelvin
|
Jul/Aug 2022
Pg. 298-301
|
Drug Shortages & Discontinued Drugs: The Effects on Patients and Healthcare Providers
Allen Loyd V Jr, Williams LaVonn A
|
Jul/Aug 2012
Pg. 294-298
|
Roboticized Compounding of Oncology Drugs in a Hospital Pharmacy
Palma Elisabetta, Bufarini Celestino
|
Sep/Oct 2014
Pg. 358-364
|
PreScription: Discontinued Drugs and Drug Shortages
Allen Loyd V Jr
|
Mar/Apr 2011
Pg. 92
|
Return to Top |